Skip to main content
Premium Trial:

Request an Annual Quote

Ceres, Genset Sign Collaborative Agreement In Agricultural Genomics


LOS ANGELES--Ceres, an agricultural genomics company here, has agreed to collaborate with French genomics firm Genset in the area of agricultural genetics. The partnership gives Ceres an exclusive license to use some of Genset's mapping, sequencing, and bioinformatics technologies. In addition, Ceres will establish independent operations in Evry, France, adjacent to Genset's Genomics Research Center, to facilitate the alliance.

Genset will retain exclusive rights to all discoveries generated by the collaboration that have applications in human health, and has acquired a 20 percent equity stake in Ceres. In addition, the French firm will receive service fees over the term of the agreement and acquire more equity upon reaching certain milestones. Pascal Brandys, Genset's chairman and CEO, has also joined Ceres's Board of Directors.

"This is an excellent opportunity to apply Genset's genomics expertise to a new and very large commercial area," Brandys remarked. "The alliance will provide an additional revenue stream without detracting from our principle business of providing genomics solutions to our pharmaceutical partners."

Ceres, led by Walter De Logi, is funded by Oxford Bioscience Partners. The company is focused on assembling and applying a broad-based platform of plant genomics technologies.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.